![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Department of Molecular and Cellular Physiology, Stanford University, Stanford, California (K.D.M., S.J.S.); and Department of CNS Biology, Pfizer Global Research & Development, Ann Arbor, Michigan (C.P.T.)
Pregabalin [S-[+]-3-isobutylGABA or (S)-3-(aminomethyl)-5-methylhexanoic acid, Lyrica] is an anticonvulsant and analgesic medication that is both structurally and pharmacologically related to gabapentin (Neurontin; Pfizer Inc., New York, NY). Previous studies have shown that pregabalin reduces the release of neurotransmitters in several in vitro preparations, although the molecular details of these effects are less clear. The present study was performed using living cultured rat hippocampal neurons with the synaptic vesicle fluorescent dye probe FM4-64 to determine details of the action of pregabalin to reduce neurotransmitter release. Our results indicate that pregabalin treatment, at concentrations that are therapeutically relevant, slightly but significantly reduces the emptying of neurotransmitter vesicles from presynaptic sites in living neurons. Dye release is reduced in both glutamic acid decarboxylase (GAD)-immunoreactive and GAD-negative (presumed glutamatergic) synaptic terminals. Furthermore, both calcium-dependent release and hyperosmotic (calcium-independent) dye release are reduced by pregabalin. The effects of pregabalin on dye release are masked in the presence of L-isoleucine, consistent with the fact that both of these compounds have a high binding affinity to the calcium channel 
2-
protein. The effect of pregabalin is not apparent in the presence of an N-methyl-D-aspartate (NMDA) antagonist [D(-)-2-amino-5-phosphonopentanoic acid], suggesting that pregabalin action depends on NMDA receptor activation. Finally, the action of pregabalin on dye release is most apparent before and early during a train of electrical stimuli when vesicle release preferentially involves the readily releasable pool.
Address correspondence to: Dr. Kristina D. Micheva, Department of Molecular and Cellular Physiology, Stanford University, Stanford, CA 94305. E-mail: kmicheva{at}stanford.edu
Related articles in MolPharm:
This article has been cited by other articles:
|
|
 |
|
  J. Hendrich, A. T. Van Minh, F. Heblich, M. Nieto-Rostro, K. Watschinger, J. Striessnig, J. Wratten, A. Davies, and A. C. Dolphin Pharmacological disruption of calcium channel trafficking by the {alpha}2{delta} ligand gabapentin PNAS, March 4, 2008; 105(9): 3628 - 3633. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. M. Gajraj Pregabalin: Its Pharmacology and Use in Pain Management Anesth. Analg., December 1, 2007; 105(6): 1805 - 1815. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. P. Kruszewski, J. A. Shane, P .J. Siddall, M . Cousins, A . Otte, T . Griesing, R . Chambers, and K . Murphy PREGABALIN IN CENTRAL NEUROPATHIC PAIN ASSOCIATED WITH SPINAL CORD INJURY: A PLACEBO-CONTROLLED TRIAL Neurology, June 12, 2007; 68(24): 2158 - 2160. [Full Text] [PDF]
|
|
|
|
 |
|
 R. W. Holz Pharmacology Meets Vesicular Trafficking at a Central Nervous System Synapse: Pregabalin Effects on Synaptic Vesicle Cycling in Hippocampal Neurons Mol. Pharmacol., August 1, 2006; 70(2): 444 - 446. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
